0000899243-21-014183.txt : 20210331 0000899243-21-014183.hdr.sgml : 20210331 20210331163016 ACCESSION NUMBER: 0000899243-21-014183 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200831 FILED AS OF DATE: 20210331 DATE AS OF CHANGE: 20210331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zordani Richard A. Jr. CENTRAL INDEX KEY: 0001827180 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 21793819 MAIL ADDRESS: STREET 1: 467 N. COUNTRY RIDGE CT. CITY: LAKE ZURICH STATE: IL ZIP: 60047 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-08-31 0 0001133416 GALECTIN THERAPEUTICS INC GALT 0001827180 Zordani Richard A. Jr. C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS, GA 30071 1 0 0 0 Common Stock 14583 D Warrants to Purchase Common Stock 7.00 2019-05-28 2026-05-28 Common Stock 770 D EXHIBITS LIST: Exhibit 24.1 - Power of Attorney /s/ Jack W. Callicutt, by Power of Attorney 2021-03-29 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT
                               POWER OF ATTORNEY
                 FOR SEC FILINGS ON FORMS ID, 3, 4, 5 AND 144
                          IN RESPECT OF SECURITIES OF
                           GALECTIN THERAPEUTICS INC.

    The undersigned hereby constitutes and appoints each of Jack W. Callicutt,
Joel Lewis, Robert Tritt and Wing Shing Lee as his true and lawful attorney-in-
fact and agent, with full power of substitution and resubstitution for him in
his name and stead in any and all capacities, to sign and file for and on his
behalf, in respect of any acquisition, disposition or other change in ownership
of any Common Stock or derivative securities thereof of Galectin Therapeutics
Inc. (the "Company"), the following:

    (i)     any Form ID to be filed with the Securities and Exchange Commission
            (the "SEC");

    (ii)    any Initial Statement of Beneficial Ownership of Securities on Form
            3 to be filed with the SEC;

    (iii)   any Statement of Changes of Beneficial Ownership of Securities on
            Form 4 to be filed with the SEC;

    (iv)    any Annual Statement of Beneficial Ownership of Securities on Form 5
            to be filed with the SEC;

    (v)     any Notice of Proposed Sale of Securities on Form 144 to be filed
            with the SEC; and

    (vi)    any and all agreements, certificates, receipts, or other documents
            in connection therewith. The undersigned hereby gives full power and
            authority to the attorney-in-fact to seek and obtain as the
            undersigned's representative and on the undersigned's behalf,
            information on transactions in the Company's securities from any
            third party, including brokers, employee benefit plan administrators
            and trustees, and the undersigned hereby authorizes any such person
            to release such information to the undersigned and approves and
            ratifies any such release of information. The undersigned hereby
            grants unto such attorney-in-fact and agent full power and authority
            to do and perform each and every act and thing requisite and
            necessary in connection with such matters and hereby ratifies and
            confirms all that any such attorney-in-fact and agent or substitute
            may do or cause to be done by virtue hereof. The undersigned
            acknowledges that:


         (i)  neither the Company nor such attorney-in-fact assumes (i) any
              liability for the undersigned's responsibility to comply with the
              requirement of the Securities Exchange Act of 1934, as amended
              (the "Exchange Act"), (ii) any liability of the undersigned for
              any failure to comply with such requirements or (iii) any
              obligation or liability of the undersigned for profit disgorgement
              under Section 16(b) of the Exchange Act; and

         (ii) this Power of Attorney does not relieve the undersigned from
              responsibility for compliance with the undersigned's obligations
              under the Exchange Act, including without limitation the reporting
              requirements under Section 16 of the Exchange Act. This Power of
              Attorney shall remain in full force and effect until revoked by
              the undersigned in a signed writing delivered to such attorney-in-
              fact.


         IN WITNESS WHEREOF, the undersigned has executed this Power of
         Attorney.


Date:  March 26, 2021    /s/ Richard A. Zordani
                        ------------------------------------------------
                          Richard A. Zordani